CA3225438A1 - Methods of intravenous adminstration of glyburide and other drugs - Google Patents

Methods of intravenous adminstration of glyburide and other drugs Download PDF

Info

Publication number
CA3225438A1
CA3225438A1 CA3225438A CA3225438A CA3225438A1 CA 3225438 A1 CA3225438 A1 CA 3225438A1 CA 3225438 A CA3225438 A CA 3225438A CA 3225438 A CA3225438 A CA 3225438A CA 3225438 A1 CA3225438 A1 CA 3225438A1
Authority
CA
Canada
Prior art keywords
glyburide
administration
bolus
drug
time
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3225438A
Other languages
English (en)
French (fr)
Inventor
Sven Martin Jacobson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Remedy Pharmaceuticals Inc
Original Assignee
Remedy Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remedy Pharmaceuticals Inc filed Critical Remedy Pharmaceuticals Inc
Publication of CA3225438A1 publication Critical patent/CA3225438A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Anesthesiology (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
CA3225438A 2010-07-19 2011-07-18 Methods of intravenous adminstration of glyburide and other drugs Pending CA3225438A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36568910P 2010-07-19 2010-07-19
US61/365,689 2010-07-19
CA3101711A CA3101711C (en) 2010-07-19 2011-07-18 Methods of intravenous administration of glyburide and other drugs

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA3101711A Division CA3101711C (en) 2010-07-19 2011-07-18 Methods of intravenous administration of glyburide and other drugs

Publications (1)

Publication Number Publication Date
CA3225438A1 true CA3225438A1 (en) 2012-01-26

Family

ID=45497399

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3225438A Pending CA3225438A1 (en) 2010-07-19 2011-07-18 Methods of intravenous adminstration of glyburide and other drugs
CA2806069A Active CA2806069C (en) 2010-07-19 2011-07-18 Methods of intravenous administration of glyburide and other drugs
CA3101711A Active CA3101711C (en) 2010-07-19 2011-07-18 Methods of intravenous administration of glyburide and other drugs

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2806069A Active CA2806069C (en) 2010-07-19 2011-07-18 Methods of intravenous administration of glyburide and other drugs
CA3101711A Active CA3101711C (en) 2010-07-19 2011-07-18 Methods of intravenous administration of glyburide and other drugs

Country Status (7)

Country Link
US (9) US8946293B2 (https=)
EP (3) EP3339190A1 (https=)
JP (5) JP6188021B2 (https=)
KR (8) KR20250026419A (https=)
CN (2) CN109172363A (https=)
CA (3) CA3225438A1 (https=)
WO (1) WO2012012347A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010247800A1 (en) 2009-05-11 2011-12-15 Berg Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
EP3339190A1 (en) 2010-07-19 2018-06-27 Biogen Chesapeake LLC Containers for glyburide solutions
HUE045889T2 (hu) * 2010-10-21 2020-01-28 Rtu Pharmaceuticals Llc Használatkész ketorolak készítmények
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
JP6238969B2 (ja) 2012-05-08 2017-11-29 エアロミクス・インコーポレイテッドＡｅｒｏｍｉｃｓ，Ｉｎｃ． 新規方法
SG10201903112WA (en) 2013-04-08 2019-05-30 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
KR102370843B1 (ko) * 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
WO2015069956A2 (en) 2013-11-06 2015-05-14 Aeromics, Llc Novel formulations
MX384247B (es) 2015-05-29 2025-03-14 Univ Maryland Antagonistas del sur1- trpm4 para usarse para reducir o prevenir daño a la íntima provocado por estimulación mecánica de células endoteliales.
CA3001321A1 (en) * 2015-10-07 2017-04-13 Biogen Chesapeake Llc Methods of treating injuries or conditions related to cns edema
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
JP7165648B2 (ja) 2016-07-29 2022-11-04 バイオジェン チェサピーク エルエルシー Ｓｕｒ１－ｔｒｐｍ４チャネル阻害剤による医療処置方法
WO2018204721A1 (en) 2017-05-05 2018-11-08 Nino Sorgente Methods and compositions for improving eye health
US11382881B2 (en) 2017-05-05 2022-07-12 Nino Sorgente Methods and compositions for diagnosing and treating glaucoma
CN108078999B (zh) * 2017-12-22 2020-08-14 沈阳药科大学 用于防治缺血性脑卒中的药物组合物及其制备方法和用途
CN120004770A (zh) 2020-07-17 2025-05-16 上海森辉医药有限公司 磺酰脲类衍生物及其医药用途
US12251389B1 (en) 2024-04-22 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
US12251388B1 (en) 2024-05-09 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856360A (en) * 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
DE10300323A1 (de) * 2003-01-09 2004-10-14 Baxter Healthcare S.A. Sicherheitsbehälter mit erhöhter Bruch und Splitterfestigkeit sowie kontaminationsfreier Außenfläche für biologisch aktive Substanzen und Verfahren zu deren Herstellung
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
EP2438913B1 (en) 2002-03-20 2020-05-06 University of Maryland, Baltimore A non-selective cation channel in neural cells and compounds that block the channel for use in treating brain swelling
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
US20040073192A1 (en) * 2002-10-15 2004-04-15 Flament-Garcia Mary Jane Intravenous fluid delivery set
US20050148928A1 (en) * 2003-12-31 2005-07-07 Medtronic Minimed, Inc. Multiple layer tubing and method of making same
CN1960735B (zh) 2004-05-20 2015-07-29 代阿麦迪卡股份有限公司 药物组合在治疗胰岛素抗性中的应用
AU2005287090A1 (en) 2004-09-18 2006-03-30 Department Of Veterans Affairs Therapeutic agents targeting the NCca-ATP channel and methods of use thereof
JP5307397B2 (ja) * 2004-09-18 2013-10-02 ユニバーシティ オブ メリーランド，ボルチモア ＮＣＣａ−ＡＴＰチャネルを標的とする治療剤およびその使用方法
AU2005322136B2 (en) * 2004-12-23 2011-01-06 Hospira, Inc. Port closure system for intravenous fluid container
HRP20130150T1 (hr) * 2006-09-29 2013-03-31 Infa S.A. Sustav pakiranja farmaceutskih sastava i komplet za intravenozno davanje
WO2009002832A2 (en) 2007-06-22 2008-12-31 University Of Maryland, Baltimore Inhibitors of ncca-atp channels for therapy
US20110034560A1 (en) * 2008-01-29 2011-02-10 Sven Jacobson Liquid formulations of compounds active at sulfonylurea receptors
CN101229316B (zh) * 2008-01-31 2010-08-25 广东药学院 一种知母提取物
EP3339190A1 (en) 2010-07-19 2018-06-27 Biogen Chesapeake LLC Containers for glyburide solutions

Also Published As

Publication number Publication date
KR20220000943A (ko) 2022-01-04
KR101917975B1 (ko) 2018-11-13
EP3586850A1 (en) 2020-01-01
JP6506335B2 (ja) 2019-04-24
US10391053B2 (en) 2019-08-27
KR20200054319A (ko) 2020-05-19
CA2806069A1 (en) 2012-01-26
US20150157560A1 (en) 2015-06-11
JP2013532658A (ja) 2013-08-19
US9254259B2 (en) 2016-02-09
CA2806069C (en) 2021-01-19
KR20130133165A (ko) 2013-12-06
KR20250026419A (ko) 2025-02-25
US10052280B2 (en) 2018-08-21
US9561176B2 (en) 2017-02-07
KR20170118960A (ko) 2017-10-25
JP6188021B2 (ja) 2017-08-30
US10786445B2 (en) 2020-09-29
KR20230165363A (ko) 2023-12-05
US20130203853A1 (en) 2013-08-08
CA3101711C (en) 2024-02-13
CN103108637B (zh) 2018-09-14
CN103108637A (zh) 2013-05-15
US20210154135A1 (en) 2021-05-27
EP2595633A4 (en) 2014-01-22
US20250221924A1 (en) 2025-07-10
US20160030370A1 (en) 2016-02-04
JP2017105846A (ja) 2017-06-15
US12226521B2 (en) 2025-02-18
KR20180123176A (ko) 2018-11-14
AU2011279878A1 (en) 2013-03-07
JP2019038855A (ja) 2019-03-14
US11559481B2 (en) 2023-01-24
JP6179574B2 (ja) 2017-08-16
WO2012012347A2 (en) 2012-01-26
EP3339190A1 (en) 2018-06-27
US20170333340A1 (en) 2017-11-23
EP2595633A2 (en) 2013-05-29
CA3101711A1 (en) 2012-01-26
WO2012012347A3 (en) 2012-05-10
JP2020073595A (ja) 2020-05-14
US20230414489A1 (en) 2023-12-28
KR20190031592A (ko) 2019-03-26
JP6795571B2 (ja) 2020-12-02
US20170348227A1 (en) 2017-12-07
US20190328653A1 (en) 2019-10-31
US8946293B2 (en) 2015-02-03
CN109172363A (zh) 2019-01-11
JP2016020393A (ja) 2016-02-04

Similar Documents

Publication Publication Date Title
US12226521B2 (en) Methods of intravenous administration of glyburide
AU2011279878B2 (en) Methods of intravenous administration of glyburide and other drugs
Class et al. Patent application title: METHODS OF INTRAVENOUS ADMINISTRATION OF GLYBURIDE
HK40020325A (en) Methods of intravenous administration of glyburide and other drugs
HK40002343A (en) Methods of intravenous administration of glyburide and other drugs
HK1185276B (en) Methods of intravenous administration of glyburide and other drugs
HK1185276A (en) Methods of intravenous administration of glyburide and other drugs

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240404

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250403

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250626

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250626

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250801

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250804

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250912

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250912